MedTrace Logo

Registry of Patients Having Received oNKord®

NCT05290662 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-08-04

No results posted yet for this study

Summary

ReKORD is an observational study (Registry) enrolling participants who have received at least one dose of oNKord® (allogeneic ex vivo-generated Natural Killer \[NK\] cells from CD34+ umbilical cord blood progenitor cells) in a clinical trial. Participants from multiple previous clinical trials of oNKord® can be enrolled in this Registry.

Conditions

Interventions

DRUG

oNKord®

Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells

DRUG

Cyclophosphamide/Fludarabine (Cy/Flu)

Lymphodepleting conditioning regimen

Sponsors & Collaborators

  • Glycostem Therapeutics BV

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-14
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05290662 on ClinicalTrials.gov